MetaCap

NovoCure (NVCR) vs SpyGlass Pharma (SGP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NovoCure is the larger company by market cap ($1.25 billion vs $1.02 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVCR+5.62%SGP+15.27%
+104%+32%-40%
Feb 6, 20261 yearNov 20, 2026
NVCR+5.62%SGP+15.27%
+82%+23%-36%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVCR versus SGP key metrics
MetricNVCRSGP
Share price$10.71$30.43
Market cap$1.25B$1.02B
1-day change+0.19%-1.14%
YTD return-17.17%—
1-year return-10.38%—
5-year return-88.96%—
EPS (TTM)$-1.06$-2.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$655.35M—
Revenue growth (YoY)+8.28%—
Net income (latest FY)$-136.23M$-39.87M
Gross margin74.54%—
Operating margin-23.47%—
Net margin-20.79%—
52-week high$21.45$39.92
52-week low$9.82$17.06
Distance from 52-week high-50.07%-23.77%
Analyst consensusbuystrong_buy
Avg. price target upside+144.07%+53.37%
Average volume1.51M114.63K
Shares outstanding116.92M33.46M
Employees1,60588
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About NovoCure

NVCR stock →

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.

Health Care · Medical/Dental Instruments · 1,605 employees

About SpyGlass Pharma

SGP stock →

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.

Health Care · Medical/Dental Instruments · 88 employees

NVCR vs SGP FAQ

Which is bigger, NovoCure or SpyGlass Pharma?

NovoCure (NVCR) is larger, with a market capitalization of $1.25B compared with $1.02B for SpyGlass Pharma (SGP).

Are NovoCure and SpyGlass Pharma in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons